Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 1/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 11/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29582955 | 1.00 | HRAS (0.55) | HRASKRASCD274PDCD1MAP4K1 | |
| SCHEMBL21198553 | 0.84 | HRAS (0.55) | HRASKRASCD274PDCD1MAP4K1 | |
| SCHEMBL30222513 | 0.79 | HRAS (0.40) | HRASKRASCD274PDCD1PDCD1LG2 | |
| SCHEMBL21198364 | 0.79 | HRAS (0.40) | HRASKRASCD274PDCD1PDCD1LG2 | |
| SCHEMBL21198361 | 0.78 | HRAS (0.38) | HRASKRASCD274PDCD1PDCD1LG2 | |
| SCHEMBL25003676 | 0.78 | CD274 (0.41) | HRASKRASCD274PDCD1PDCD1LG2 | |
| SCHEMBL21198350 | 0.78 | HRAS (0.48) | HRASKRASCD274PDCD1MAP4K1 | |
| SCHEMBL21198397 | 0.77 | HRAS (0.80) | HRASKRASCD274PDCD1MAP4K1 | |
| SCHEMBL21198058 | 0.76 | HRAS (0.43) | HRASKRASCD274PDCD1MAP4K1 | |
| SCHEMBL30222380 | 0.76 | HRAS (0.43) | HRASKRASCD274PDCD1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | HRAS 932/4885KRAS 681/4885CD274 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.